Difference between revisions of "Bristol-Myers Squibb"
(starting new page) |
(adding more affiliations) |
||
| Line 8: | Line 8: | ||
:'Under the terms of the agreement, Bristol-Myers Squibb will provide committed funds of approximately $30 million over the next three years to Adnexus... Adnexus also is eligible to receive regulatory milestone payments of up to $210 million per product, as well as royalties on product sales and sales-based milestone payments'. | :'Under the terms of the agreement, Bristol-Myers Squibb will provide committed funds of approximately $30 million over the next three years to Adnexus... Adnexus also is eligible to receive regulatory milestone payments of up to $210 million per product, as well as royalties on product sales and sales-based milestone payments'. | ||
| + | BMS also entered into partnership with [[AstraZeneca]] in 2007 to 'develop and commercialize' compounds for the treatment of type 2 diabetes<ref> BMS [http://newsroom.bms.com/index.php?s=press_releases&item=230 Bristol-Myers Squibb and AstraZeneca Announce Worldwide Collaboration to Develop and Commercialize Diabetes Compounds] Accessed 16th December 2007</ref>. | ||
| + | |||
| + | In 2007, Bristol-Myers Squibb also announced an alliance with [[Gilead Sciences, Inc]] to commercialize ATRIPLA(R) (for the treatment of HIV-1)<ref> BMS [http://investor.bms.com/phoenix.zhtml?c=106664&p=irol-newsArticle&ID=1086072&highlight= Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe] Accessed 16th December 2007</ref>. BMS report that, if approved, 'ATRIPLA would represent the first and only once-daily single tablet regimen for HIV-1 infection in the European Union'. In order to commercialize ATRIPLA, Bristol-Myers Squibb reached an agreement with [[Merck and Co. Inc.]] who previously had the exclusive right to market any product containing efavirenz (a component of ATRIPLA) in all European countries other than the United Kingdom, Germany, France, Italy, Spain and the Republic of Ireland. | ||
| + | |||
| + | In 2006, Bristol-Myers Squibb Company announced that [[Otsuka Pharmaceutical Co., Ltd.]] had been granted exclusive rights in Japan to develop and commercialize the investigational compound saxagliptin (a treatment discovered by BMS for the treatment of Type 2 diabetes).<ref> BMS [http://newsroom.bms.com/index.php?s=press_releases&item=227 Bristol-Myers Squibb and Otsuka Pharmaceutical Co., Ltd. Announce Exclusive Licensing Agreement for Diabetes Compound Saxagliptin in Japan] Accessed 16th December 2007</ref> | ||
| + | |||
| + | |||
==References== | ==References== | ||
<references/> | <references/> | ||
[[Category:Pharmaceutical Industry]] | [[Category:Pharmaceutical Industry]] | ||
Revision as of 13:30, 16 December 2007
Affiliations
In 2007 Bristol-Myers Squibb (BMS) announced collaboration with Isis Pharmaceuticals Inc. in the development of cardiovascular disease treatment[1].
2007 also saw BMS enter in partnership with Pfizer for a worldwide collaboration to develop and commercialize apixaban (an anticoagulant for the prevention and treatment of a broad range of venous and arterial thrombotic conditions). BMS also reports that 'in a separate agreement, the companies will also collaborate on the research, development and commercialization of a Pfizer discovery program which includes advanced pre-clinical compounds with potential applications for the treatment of metabolic disorders, including obesity and diabetes'.[2]
In February 2007, Bristol-Myers Squibb Company (NYSE: BMY) and Adnexus Therapeutics announced a worldwide strategic alliance to discover, develop and commercialize Adnectin-based therapeutics for oncology-related targets[3].
- 'Under the terms of the agreement, Bristol-Myers Squibb will provide committed funds of approximately $30 million over the next three years to Adnexus... Adnexus also is eligible to receive regulatory milestone payments of up to $210 million per product, as well as royalties on product sales and sales-based milestone payments'.
BMS also entered into partnership with AstraZeneca in 2007 to 'develop and commercialize' compounds for the treatment of type 2 diabetes[4].
In 2007, Bristol-Myers Squibb also announced an alliance with Gilead Sciences, Inc to commercialize ATRIPLA(R) (for the treatment of HIV-1)[5]. BMS report that, if approved, 'ATRIPLA would represent the first and only once-daily single tablet regimen for HIV-1 infection in the European Union'. In order to commercialize ATRIPLA, Bristol-Myers Squibb reached an agreement with Merck and Co. Inc. who previously had the exclusive right to market any product containing efavirenz (a component of ATRIPLA) in all European countries other than the United Kingdom, Germany, France, Italy, Spain and the Republic of Ireland.
In 2006, Bristol-Myers Squibb Company announced that Otsuka Pharmaceutical Co., Ltd. had been granted exclusive rights in Japan to develop and commercialize the investigational compound saxagliptin (a treatment discovered by BMS for the treatment of Type 2 diabetes).[6]
References
- ↑ BMS Bristol-Myers Squibb Enters Cardiovascular Disease Collaboration With Isis Pharmaceuticals Accessed 16th December 2007
- ↑ BMS Bristol-Myers Squibb and Pfizer Announce Worldwide Collaboration to Develop and Commercialize Anticoagulant and Metabolic Compounds Accessed 16th December 2007
- ↑ BMS Bristol-Myers Squibb Company and Adnexus Therapeutics Announce Collaboration to Develop and Commercialize Innovative Oncology Compounds Accessed 16th December 2007
- ↑ BMS Bristol-Myers Squibb and AstraZeneca Announce Worldwide Collaboration to Develop and Commercialize Diabetes Compounds Accessed 16th December 2007
- ↑ BMS Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe Accessed 16th December 2007
- ↑ BMS Bristol-Myers Squibb and Otsuka Pharmaceutical Co., Ltd. Announce Exclusive Licensing Agreement for Diabetes Compound Saxagliptin in Japan Accessed 16th December 2007
